Ask about this productRelated genes to: ERAS Blocking Peptide
- Gene:
- ERAS NIH gene
- Name:
- ES cell expressed Ras
- Previous symbol:
- HRAS2, HRASP
- Synonyms:
- -
- Chromosome:
- Xp11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2015-08-25
Related products to: ERAS Blocking Peptide
Related articles to: ERAS Blocking Peptide
- To Explore the Safety and Feasibility of the Enhanced Recovery After Surgery (ERAS) in the Perioperative Clinical Application for Patients with Lung Cancer. - Source: PubMed
Publication date: 2026/06/12
Xiao DuanDeng PengFeng ZhihongYao ChiYuan Bing - Outdoor space applications of ultra-low-volume (ULV) insecticides are widely used for adult mosquito management, but public concerns persist about their potential effects on non-target arthropods. Therefore, we conducted a systematic review and analysis to evaluate evidence from global peer-reviewed operational studies, field studies simulating operational studies, and modeled ecological risk assessments (ERA). A total of 38 articles met inclusion criteria, representing 43 distinct studies across multiple arthropod taxa and 10 insecticidal active ingredients. Study types comprised 25 field experiments, nine operational applications, and nine ERAs. We recorded the presence or absence of acute mortality effects on non-target arthropods and analyzed associations using Fisher's exact test and Firth logistic regression. Operational studies-representing large-scale, real-world mosquito control applications-had no deleterious effects across all taxa and insecticides. In contrast, field studies documented effects in 15 of 25 cases, although results were equivocal, with 10 studies finding no effects despite conditions favoring direct exposure (eg caged insects placed in the direct aerosol path). The ERAs showed mixed outcomes, most likely reflecting their intentionally conservative design. Study type was strongly associated with effect detection (P < 0.001), with operational applications significantly less likely to report effects. Overall, evidence suggests that risks to non-target arthropod populations from operational ULV mosquito adulticide applications are low, primarily due to reduced exposure from nighttime treatments, aerosol droplet characteristics (size and volume), rapid dispersal, and rapid breakdown. Increased emphasis on operational-scale research is needed to strengthen the understanding of risks for non-target arthropods. - Source: PubMed
Peterson Robert K DKennedy Taylor EStrand Jackson R - Enhanced Recovery After Surgery (ERAS) protocols represent a multidisciplinary strategy designed to optimize perioperative management and accelerate postoperative recovery. However, their adoption in vascular surgery-particularly in open aortic procedures-remains limited due to procedural complexity and the large number of elements required for implementation. In other surgical specialties, specific perioperative components have been identified as key determinants of outcome improvement, with adherence rates exceeding 70% considered essential to achieve significant clinical benefits. The aim of this study was to identify the core elements within an ERAS protocol for open aortic surgery that most significantly influence outcomes, and to evaluate the impact of overall protocol adherence on postoperative results. - Source: PubMed
Publication date: 2026/06/12
Campolmi MarcoSpeziali SaraScafa AnnamariaFalso RobertoCasini AndreaBaldini GabrieleDorigo WalterPulli RaffaeleGiacomelli Elena - A preoperative pain catastrophising scale (PCS) of >20 is associated with increased postoperative pain, development of chronic pain, and impaired function after hip and knee arthroplasty. However, whether PCS >20 is associated with prolonged length of hospital stay (LOS), readmissions, and reduced likelihood of same-day discharge is unknown.The primary aim of this study was to investigate the association between a preoperative PCS of >20 and a LOS >2 days Secondary aims were to investigate the association of PCS >20 with 90-day readmission rate and admission postoperatively. - Source: PubMed
Publication date: 2026/06/01
Jørgensen Christoffer CKornvig SimonKehlet HenrikLindberg-Larsen MartinGromov KirillBieder Manuel JAndersen Mikkel ROvergaard SørenHansen Torben BJakobsen ThomasVarnum Claus - The oligometastatic paradigm has expanded the use of stereotactic ablative radiotherapy (SABR) and local consolidative therapy (LCT) in metastatic non-small cell lung cancer (NSCLC), but accumulating evidence suggests that 'oligometastatic NSCLC' is not a single clinical entity. As systemic therapy has advanced-particularly third-generation EGFR tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors-both the intent and the incremental value of local therapy have diverged by molecular subtype, metastatic tempo and treatment setting. In EGFR-mutated disease, multiple prospective studies now support LCT as a strategy to extend durable benefit from TKIs by ablating limited sites of disease, with contemporary randomised data emerging in the osimertinib era and ongoing trials addressing optimal timing and completeness of consolidation. In driver-negative, immunotherapy-treated NSCLC, early phase and real-world series suggest that carefully selected patients can achieve durable control within multimodality pathways, but the most practice-defining randomised evidence to date has not supported routine consolidation for all non-progressing patients and highlights pneumonitis risk, reinforcing the need for stringent staging and selection. Management of EGFR-mutated small and non-symptomatic brain metastases has similarly evolved towards systemic-first sequencing with selective stereotactic radiosurgery for high-risk lesions or focal central nervous system escape, informed by emerging randomised data. Across settings, lesion count alone is an imperfect surrogate for biology; metastatic tempo, molecular drivers and treatment response patterns are increasingly relevant to deciding when SABR should be comprehensive, selective or deferred. Ongoing trials in targeted and immunotherapy eras will determine when LCT should be integrated as standard care versus an optimisation strategy for a minority. We propose a pragmatic framework centred on treatment intent-comprehensive ablation for potentially curable limited disease versus focal ablation to maintain an effective systemic agent-aimed at supporting multidisciplinary decision-making as the evidence base evolves. - Source: PubMed
Publication date: 2026/06/05
O'Dwyer NiallPalma David A